V ascular calcification is a common complication of chronic kidney disease, atherosclerosis, and diabetes mellitus. 1, 2 It is directly related to cardiovascular morbidity and mortality. 3, 4 Previously viewed as an inevitable, passive, and degenerative process, vascular calcification is increasingly being considered a complex and regulated process, with great similarities to skeletal mineralization. 1, 5, 6 These findings have led to the important question of which cell types give rise to the skeletal elements of calcified arteries and what mechanisms regulate vascular calcification. To date, substantive studies have demonstrated that vascular smooth muscle cells (VSMCs) retain multipotential capability and can transform into osteo-/chondrocytic-like cells and express genes that are typically expressed by osteoblasts and chondrocytes during osteogenesis. [7] [8] [9] [10] Several factors facilitate osteochondrogenic transition of VSMCs and vascular calcification, including high calcium-phosphate products, oxidative stress, bone morphogenetic proteins (BMPs) (BMP-2, -4, -6), and vitamin D. Alternatively, loss of inhibitors of mineralization, such as matrix Gla protein (MGP) and osteopontin, also predispose vascular calcification. 5, 11, 12 A finely tuned balance between inducers and inhibitors likely controls whether calcification occurs under pathological conditions. Other important mechanisms including apoptosis, mineral imbal-ance, or inflammation have also been involved in the pathogenesis of dystrophic calcification. 1, 6, 12 However, the underlying molecular and cellular mechanisms of arterial calcification are still not fully understood.
Cartilage oligomeric matrix protein (COMP) is a 524-kDa pentameric noncollagenous glycoprotein expressed in all types of cartilage, vitreous of the eye, tendons, and VSMCs. 13 Immunohistological staining of articular cartilage has revealed a developmentally regulated localization of COMP to the hypertrophic zone of the growth plate and in the superficial layer of the articular cartilage surface, but little detection in mineralized bone. 14, 15 In addition, COMP is recently identified as a normal component of the human artery wall and secreted by VSMCs. 13 Of interest, COMP was also detected in areas of microcalcification in human atherosclerotic lesions but not in calcific foci within the lesions. 16 The importance of COMP for chondrogenesis and skeletal development has been underscored by the identification of COMP mutations in two different inherited chondrodysplasias and osteoarthrotic phenotypes: pseudoachondroplasia and multiple epithelial dysplasia. 17 In contrast, little is known about the function of COMP in arteries.
Recently, our studies suggested that COMP is essential for maintaining the quiescent/contractile phenotype of VSMCs. Ablation or degradation of COMP led to phenotypic transition and disturbance of VSMC homeostasis. 18, 19 Considering the similarities between bone mineralization and vascular calcification, the distinct localization pattern of COMP in Figure 1 . COMP protein level is decreased in calcifying VSMCs and arteries. A, Representative Western blot and quantitative analysis of COMP protein in bovine VSMCs cultured in calcifying medium containing 10 mmol/L ␤-GP for 3, 5, and 7 days. Relative COMP protein level was normalized to that of ␤-actin and expressed as meansϮSEM from 3 independent experiments performed in duplicate (bottom). *PϽ0.05. B, COMP protein level in A7r5 cells exposed to 5 mmol/L CaCl 2 for 3, 6, 9, and 12 days. C, Representative Western blot and quantitative analysis of COMP protein in abdominal aortas from shamoperated or rats with CRF (5/6 nephrectomization plus high phosphate diet) at time of euthanasia (nϭ7 per group). *PϽ0.05 vs sham control. D, COMP expression in rat abdominal aortas periadventitially treated with 0.2 mol/L NaCl or CaCl 2 (nϭ5 per group). *PϽ0.05.
skeletal and calcified vascular tissues, the importance of COMP in chondrogenesis and in VSMC phenotype transition, we hypothesized that COMP could be an important regulator of VSMC mineralization and vascular calcification. Therefore, we used in vitro and in vivo models to investigate COMP as a novel endogenous modulator of VSMC calcification. We also investigated the involvement of BMP-2 in the effect of COMP on the osteogenic transition of VSMCs.
Methods
Animal care and use of 5/6 nephrectomy and CaCl 2 abdominal artery injury model in male Sprague-Dawley rats were in accordance with institutional guidelines. Aortic ring organ calcification was induced as described previously. 20, 21 Human radial artery specimens were collected from uremic patients during arterial venous fistular operation by the approval from the Local Research Ethics Committee.
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results

COMP Protein Level Is Decreased in Calcifying VSMCs and Arteries
A high concentration of inorganic phosphate (Pi) or calcium (Ca 2ϩ ) contributes directly to ectopic vascular calcification, although perhaps by different mechanisms. 22 Therefore, we induced mineralization by osteogenic media containing 10 mmol/L ␤-glycerophosphate (␤-GP) for BASMCs or by 5 mmol/L CaCl 2 for A7r5 cells. In vitro mineralization was verified by Alizarin red S staining, Ca accumulation and measurement of calcium deposition shown in Online Figure I (A and B). As shown in Figure 1A , full-length COMP (110 kDa) was markedly reduced at 3, 5 and 7 days in BASMCs after ␤-GP stimulation, which was paralleled by an increase in COMP degradation fragment (approximately 55 kDa). In accordance, a similar COMP protein reduction was observed in CaCl 2 -induced calcifying A7r5 cells at various stages, whereas COMP mRNA level was not changed ( Figure 1B ; Online Figure II ). To further verify this observation in vivo, we used a chronic renal failure (CRF) rat model and an abdominal aortic injury rat model to mimic the process of vascular calcification. The first model is based on the epidemiological and clinical observation that calcification of the medial layer of arteries is prevalent in CRF and may contribute to the increased incidence of cardiovascular disease in this population. 2, 4, 23 Rats in the CRF model underwent 5/6 nephrecto- mization and received a high-phosphate diet to accelerate the process of vascular calcification. 24 Based on Online Table II , CRF rats showed a significant increase in plasma level of blood urea nitrogen, creatinine, and phosphorus. Vascular calcification was successfully induced in the CRF rats, as evidenced by calcium deposition and von Kossa staining, with no calcification in sham-operated rats (Online Figure  III) . Western blot analysis revealed the COMP expression greatly reduced in abdominal arteries of CRF rats as compared with sham-operated rats ( Figure 1C) . Similarly, in the CaCl 2 -induced abdominal aortic calcification model (Online Figure IV) , COMP expression was greatly reduced, whereas the COMP degradation fragment was concomitantly increased as compared with control rats ( Figure 1D ). In contrast, COMP mRNA level was not significantly altered (Online Figure V) .
Thus, various in vitro and in vivo VSMC calcification models revealed a general reduction in COMP protein level. Combined with our recent observation that COMP is necessary to maintain the contractile phenotype of VSMCs, 18 COMP may negatively regulate the process of VSMC calcification.
COMP Deficiency Aggravates VSMC Calcification In Vitro
To further investigate the potential causal role of COMP in VSMC mineralization, we first knockdown COMP by small interfering (si)RNA and test whether COMP knockdown alone was sufficient to drive calcification in the absence of calcifying medium. Specific knockdown of COMP was verified at both the mRNA and protein levels (Online Figure  VI) . As determined biochemically and histologically, COMP silencing did not cause detectable spontaneous calcification during 12-day culture period (Online Figure VII, A and B). Nevertheless, when exposed to high calcium, COMP knockdown greatly exacerbated calcium deposition by 50% in VSMCs as compared with scramble siRNA (Figure 2A and 2B). In contrast, the deterioration effect of COMP repression was gradually circumvented by supplementation with increasing amounts of exogenous purified COMP. Additionally, primary thoracic VSMCs from COMP Ϫ/Ϫ mice showed greatly increase of susceptibility to calcification in response to high-phosphate stimulation ( Figure 2C through 2E). These in vitro data reinforce our hypothesis that COMP may act as an inhibitor of VSMC calcification.
Ectopic Expression of COMP Ameliorates VSMC Calcification In Vitro
We next asked whether overexpression of COMP could rescue the mineralization of VSMCs. We treated VSMCs with ␤-GP or CaCl 2 to induce mineralization. Adenovirus (Ad)-COMP was applied, and COMP overexpression was verified as indicated in Online Figure VIII (A and B). As shown in Figure 3A and 3C, calcium deposition was increased Ϸ16-fold by 10 mmol/L ␤-GP or 7-fold by 5 mmol/L calcium, as compared with untreated control cells. Ectopic infection with Ad-COMP greatly reduced the extent of VSMC calcification by 41% or 43% with the 2 treatments, whereas GFP adenovirus had no effect. The observation was further verified by Alizarin red S staining ( Figure 3B and 3D), which indicated that the inhibitory effect of COMP on VSMC calcification did not differ by high calcium or phosphate stimulation but rather was a general phenomenon.
Ectopic Expression of COMP Retards Vascular Calcification In Vivo
To further validate the protective effect of COMP on VSMC calcification, we adopted a rat aortic-ring organ culture model. 20, 21 The viability of the aortic ring explants was verified by MTT assay after 6 days' culture (data not shown). As indicated in Figure 4A and 4B, calcification of aortic ring was markedly induced by 3.8 mmol/L PO 4 3Ϫ stimulation for 6 days, as demonstrated by calcium deposition and von Kossa staining. Conversely, Ad-COMP-infected aortic explants (Online Figure VIII, C) showed much less calcification than Ad-GFP-infected explants. We further evaluated the protective effect of COMP in an in vivo medial calcification model induced by perivascular application of 0.2 mol/L CaCl 2 to the infrarenal abdominal aortas of rat. Ad-GFP infection did not alter the calcification deposition in the abdominal aorta. In contrast, Ad-COMP greatly suppressed the aortic calcification by 63% ( Figure 4C ; nϭ5, PϽ0.05). The intensity of von Kossa staining was significantly lower in Ad-COMP-infected aortas than in Ad-GFP-infected aortas ( Figure 4D ). Thus, COMP overexpression may inhibit both high Pi-or CaCl 2 -induced vascular calcification.
COMP Negatively Regulates Osteochondrogenic Transition of VSMCs
Previously, we showed that COMP is necessary to maintain a quiescent/contractile phenotype of VSMCs, and ablation of COMP facilitates a synthetic phenotype in response to injury. 18 Therefore, we tested whether COMP could interfere with osteogenic transition of VSMCs. Interestingly, the expression of the osteochondrogenic markers Runx2, Msx2, Sox9 and BMP-2 were markedly higher in VSMCs with siRNA knockdown of COMP than with scramble siRNA treatment ( Figure 5A drogenic transition even in the absence of calcifying microenvironment. Of note, the mRNA level of the known regulators of calcification, MGP, osteopontin and osteocalcin were not altered ( Figure 5A ). In accordance, COMP overexpression significantly circumvented the upregulation of Runx2, Msx2 and BMP-2 in high Ca 2ϩ -induced calcified VSMCs at both mRNA level ( Figure 5C ) and protein level (Online Figure IX,  B) . Reciprocal protein alteration of Runx2/BMP-2 and SM ␣-actin/SM22␣, as well as enhanced ALP activity were also observed in cultured rat aortic rings 3 days after 3.8 mmol/L PO 4 3Ϫ stimulation, which was greatly rescued by COMP overexpression ( Figure 5D ; Online Figure X) . We also monitored the onset of apoptosis because the latter has been reported to contribute to aortic ring calcification. 20 At day 3, no obvious apoptosis appeared as evidenced by cleaved caspase-3 and Bax activation whereas osteogenic transition already occurred (Online Figure XI, A and B) . At day 6, cleaved caspase-3 and Bax were significantly induced and TUNEL-positive cells were increased on phosphate stimulation. Of note, COMP overexpression partially inhibited highphosphate induced apoptosis. To minimize the interfering of apoptosis, we applied 3.0 mmol/L PO 4 3Ϫ stimulation to the aortic rings (Online Figure XII, A and B) . Six days after culture and stimulation, calcium deposition within aortic rings were significantly increased, although to a less extend compared with 3.8 mmol/L PO 4 3Ϫ . No apoptosis was detected by the end of culture. In contrast, markedly enhanced Runx2/BMP-2 and decreased SM ␣-actin/SM22␣ were observed in aortic rings which can be rescued by excessive COMP. Similarly, perivascular administration of Ad-COMP markedly rescued the upregulated Runx2 level and reciprocally downregulated SM ␣-actin/SM22␣ levels in the CaCl 2 -injured calcified vascular wall ( Figure 5E ). Collectively, the above data reinforce our hypothesis that COMP inhibits the osteogenic conversion of VSMCs and subsequent VSMCs calcification.
COMP Inhibits Osteogenic Signaling of BMP-2
Among various inducers of vascular calcification, BMP-2 is a potent stimulator of both orthotopic bone formation and osteoblastic differentiation of VSMCs. 25 Hence, we asked whether COMP modulated osteogenic transition of VSMCs by interfering with BMP-2. As shown in Figure 6A , the addition of a soluble form of bone morphogenetic protein receptor-type 1A (BMPR-IA) (1 mg/L) almost completely abolished the COMP-silencing induction in expression of the osteochondrogenic markers Runx2, Msx2, and Sox9, which suggests a BMP-2-dependent mechanism. Interestingly, enhanced BMP-2 mRNA level evoked by COMP knockdown was also greatly repressed by the soluble BMPR-IA. Of note, exogenous BMP-2 significantly unregulated endogenous BMP-2 mRNA expression in VSMCs. The data indicates that the induction of BMP-2 mRNA by COMP silencing was mainly attributable to lack of inhibition by COMP over extracellular BMP-2 ( Figure 6B ). Indeed, COMP silencing dramatically enhanced BMP-2-induced Smad1/5/8 phosphorylation and Runx2/Msx2 expression compared with that of scramble siRNA ( Figure 6C ). In accordance, COMP overexpression markedly suppressed BMP-2-induced Smad1/5/8 phosphorylation as well as downstream Runx2, Msx2 and osteocalcin expression ( Figure 6D through 6F) , suggesting COMP inhibits osteoblastic transition at least in part by interfering with BMP-2 signaling.
COMP Binds to BMP-2 In Vitro and In Vivo
To further explore the relationship between COMP and BMP-2, the HEK293 cell line stable transfected with COMP underwent coimmunoprecipitation (Co-IP) assay. Recombinant human BMP-2 (500 g/L) was added to the culture medium and incubated for 12 hours. As shown in Figure 7A , a specific COMP band was present in the immunoprecipitated complex brought down by anti-BMP-2 antibody but not by control IgG. Co-IP assay with anti-COMP antibody revealed that COMP also precipitated BMP-2. In addition, proteins from normal VSMCs and rat aortas underwent Co-IP with specific BMP-2/COMP antibodies or control IgG. The specific interaction between COMP and BMP-2 was observed as shown in Figure 7B . Next, we used an in vitro solid-phase binding assay to characterize the interaction between COMP and BMP-2. As shown in Figure 7C (left), use of anti-COMP antibody showed COMP bound to recombinant human BMP-2 but no detectable band with BSA. Accordingly, the use of anti-BMP-2 antibody showed increasing BMP-2 bound to purified COMP (right panel). Thus, COMP is capable of binding to BMP-2 directly because both COMP and BMP-2 were used as purified recombinant proteins. 
BMP-2 Binds Directly to the C Terminus of COMP
To further characterize the binding motif of COMP attributable to BMP-2 interaction, yeast 2-hybrid ␤-galactosidase assay was performed by cotransforming the yeast strain MAV203 with the pPC86 plasmids encoding full-length BMP-2 and pDBleu plasmid encoding the N terminus, EGF repeat domain, type III repeat domain, or the C terminus of mouse COMP. As shown in Figure 7D , ␤-galactosidase activity revealed that only the C terminus of COMP interacted with BMP-2 in yeast. The interaction between the COMP C-terminus and BMP-2 was also confirmed by in purified COMP underwent 10% SDS-PAGE and were incubated with purified COMP or human recombinant BMP-2. Anti-COMP or anti-BMP-2 antibodies were used for subsequent detection. BSA served as negative control. D, BMP-2 selectively binds to the C-terminal domain of COMP. Top, Schematic structure of COMP constructs used to map those domains (N-terminal, EGF-like, type III, and C-terminal) that bind to BMP-2. Presence or absence of binding between COMP domains and BMP-2 is indicated with ϩ or Ϫ, respectively. Bottom, ␤-Galactosidase activity was used to test the interaction between the C-terminal domain of COMP and BMP-2. Three independent yeast transformants for each pair of plasmids were transferred onto a nitrocellulose membrane, and ␤-galactosidase activity was determined. E, GST pull-down assay. Purified fusion protein of GST-N terminus, GST-EGF, GST-C terminus, and GST-C type III of COMP were immobilized on GSH-sepharose beads and incubated with purified BMP-2. Proteins trapped by GST fusion protein were examined by immunoblotting with anti-BMP-2 antibodies. vitro GST pull-down assay. In accordance with the yeast 2-hybrid results, only the purified GST-C terminus pulled down BMP-2 ( Figure 7E ).
COMP Inhibits BMP-2 Receptor Binding
Because our data indicated that COMP directly bound to BMP-2 through the C-terminal domain and inhibited BMP-2-induced Smad activation, we wondered whether COMP interfered with BMP-2 signaling by preventing BMP-2 from binding to membrane BMP-2 receptors. We isolated bulk membranes from rat VSMCs for analysis of specific binding of BMP-2 by a radioligand receptor binding assay. We examined uptake of 125 I-labeled BMP-2 by increasing amounts of plasma membranes of VSMCs. The binding of 125 I-labeled BMP-2 to the receptor-enriched VSMC plasma membranes was inhibited by unlabeled COMP in a concentration-dependent manner ( Figure 7F ). Furthermore, competitive inhibition of unlabeled BMP-2 (0.462 nmol/L) to 125 I-BMP-2 binding in the receptor-enriched VSMC plasma membranes was retarded in the presence of 6.5 nmol/L COMP ( Figure 7G ), so COMP inhibited BMP-2 receptor binding.
Reciprocal Alteration of COMP and BMP-2 in Uraemia Radial Arteries of Patients With End-Stage Renal Disease
To determine the potential clinical relevance of COMP in vascular calcification, we collected radial artery specimens from uremic patients who underwent arterial venous fistular operation (CRF; nϭ6) and from coronary heart disease (CHD) (nϭ8, as control) patients who underwent coronary artery bypass grafting, without complications of diabetes and chronic kidney disease. As shown in Figure 8 , BMP-2 and Runx2 expression were greatly enhanced in the uremic arteries than in control CHD radial arteries. Reciprocally, the level of full-length COMP was significantly reduced in uremic than in CHD radial arteries, concomitant with an increase in the COMP fragment, which further suggests an imbalance between BMP-2 and COMP may contribute to vascular calcification in end stage renal failure patients.
Discussion
Vascular calcification is an increasingly important clinical problem, particularly in the context of renal failure, diabetes, and atherosclerosis, and correlates with poor cardiovascular outcomes. 4 Accumulating evidence has pointed to an actively regulated, cell-mediated process of vascular calcification with competition between factors promoting calcification and inhibitors of mineralization. Our studies demonstrate that COMP, a macromolecule located both in cartilage and vessels, may act as a novel endogenous inhibitor of vascular calcification. Likewise, COMP suppressed the osteochondrogenic transition of VSMCs at least in part by interfering with BMP-2.
The cellular origins of calcified blood vessels are still controversial. Although some observations point to the activation and differentiation of nascent resident pericytes or circulating stem cells, a number of studies have indicated that the presence of osteochondrogenic cells in the vascular wall is the end result of the phenotypic change of VSMCs. 9, 26 Unlike most cell types undergoing terminal differentiation, VSMCs retain substantial phenotypic plasticity in response to injurious stimuli in the local microenvironment. 7 For example, an elevated phosphate level induces cultured VSMCs to undergo an osteochondrogenic phenotype change characterized by reduced expression of SMC markers (SM22␣, SM ␣-actin) and increased expression of osteochondrogenic markers (Runx2, osteopontin, osteocalcin, and alkaline phosphatase). 10 Nevertheless, the underlying mechanisms that control VSMC transdifferentiation to osteochondrogenic cells are still elusive. 8 The known regulatory factors include alkaline phosphatase, BMP-2, Runx2, osterix, and phosphate, among others. 1, 26 Herein, we showed COMP to be involved in VSMC osteogenic phenotypic switching by demonstrating that COMP ablation renders the transition of VSMCs to osteogenic-like cells. Reciprocally, COMP overexpression reversed the osteogenic transition in vitro and in vivo. These observations are in agreement with our recent report that COMP is essential to maintain the contractile phenotype of VSMCs. 18 Loss of expression or integrity of COMP under a calcifying microenvironment will lead to subsequent vascular calcification.
There are other possibilities of COMP inhibiting VSMC calcification. For example, COMP binds calcium, and so it could either potentially interact with mineral crystals and influence mineralization by modulating crystal formation or chelate/sequester calcium in the culture medium. The first one needs to be further elucidated. The latter is very unlikely thought because it would require roughly 20 g/L COMP to chelate 1.8 mmol/L calcium within the growth medium, which is more than 10 5 times the amount of COMP used (0.2 mg/L) according to the calcium-binding properties of COMP. 17 Secondly, apoptosis is another key factor attributes to dystrophic calcification. 20, 27 In 3.8 mmol/L PO 4 3Ϫ ex vivo vessel culture model, the inhibition of apoptosis was observed in Ad-COMP-infected vessels but not in that of Ad-GFPinfected vessels at 6 days after high-Pi stimulation, indicating a potential negative modulation of COMP on vascular apoptosis. However, it's also conceivable that the inhibition of calcification by COMP indirectly leads to reduced apoptosis resulting from the absence of nanocrystals which can induce VSMC apoptosis if uptaken. This needs to be further elucidated. Additionally, the perivascular application of CaCl 2 to induce vascular injury and in vivo calcification 28 involves complex mechanisms including inflammation, oxidative stress, apoptosis etc, and the precise mechanism of COMP inhibition of vascular calcification in vivo therefore needs to be further explored.
Long known to be essential for differentiation of osteoblastic cells, BMP-2 is increasingly being recognized as a mediator of vascular calcification. 25 BMP-2 may promote vascular calcification by increased phosphate uptake and inducing an osteogenic phenotype modulation in SMCs by binding to the receptors BMPR1 or BMPR2, which in turn phosphorylates the regulatory Smad1/5/8 and upregulates downstream key osteogenic transcription factors, including Runx2 and Msx2. 25, 29 In the present study, we demonstrated that COMP physically interacts with BMP-2 through the C-terminal domain of COMP, prevents BMP-2 receptor binding, suppresses Smad1/5/8 phosphorylation, and inhibits the expression of the downstream transcriptional factors Runx-2 and Msx-2. COMP therefore may modulate osteogenic transition of VSMCs by antagonizing BMP-2. The activity of BMP-2 is also antagonized by MGP, an inhibitor of arterial calcification, which was interfered by heat shock protein 70. 30 Combined with our observations, the complex protein-protein interaction within the matrix may actively modulate the process of calcification. Along with the progression of vascular calcification, COMP level was gradually decreased and the inhibitory effect of COMP on BMP-2 was gradually lost, which in turn enhanced BMP-2 expression. The imbalance of inducers and inhibitors of mineralization ultimately results in ectopic vascular calcification.
In summary, we revealed COMP as a novel endogenous inhibitor of vascular calcification. COMP exerts its inhibitory effect at least partially by directly binding to BMP-2 through its C-terminal domain and interfering with BMP-2 osteogenic signaling. Targeting COMP may open up new avenues for the prevention of vascular calcification in renal failure, diabetes and atherosclerosis.
What New Information Does This Article Contribute?
• COMP is an endogenous inhibitor of vascular calcification.
• COMP inhibits the osteochondrogenic transition of VSMCs.
• COMP directly binds to bone morphogenetic protein (BMP)-2 and therefore inhibits osteogenic signaling by BMP-2 during vascular calcification.
Vascular calcification is a major risk factor for the development of cardiovascular disease. It has been recently recognized as a process similar to skeletal mineralization. The osteochondrogenic cells in the calcified vascular wall mainly arise from a phenotypic change in VSMCs. However, the mechanism regulating the osteogenic transition of VSMC remains elusive. Herein, we demonstrate for the first time that cartilage oligomeric matrix protein (COMP) suppresses osteogenic transition of VSMC at least partially through direct binding to BMP-2. The imbalance between inducers (BMP-2) and inhibitors (COMP) of mineralization ultimately results in ectopic vascular calcification. COMP therefore is an endogenous inhibitor of vascular calcification. Our study advances the present knowledge of mechanisms by which vascular calcification is regulated, and it suggests that targeting COMP may be a promising therapeutic approach for ameliorating vascular calcification.
